Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.48 |
| ▸ | GAB1 | Q13480 | 4/20 | 0.48 |
| ▸ | IRS1 | P35568 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22080431 | 0.93 | KDM4E (0.54) | AKT1GAB1IRS1KDM4EPDPK1 | |
| SCHEMBL24257837 | 0.92 | TP53 (0.48) | AKT1GAB1IRS1KDM4ETDP1 | |
| SCHEMBL24257938 | 0.83 | TDP1 (0.44) | AKT1GAB1IRS1KDM4ETDP1 | |
| SCHEMBL22080432 | 0.83 | TDP1 (0.61) | TDP1 | |
| SCHEMBL22079879 | 0.81 | KDM4E (0.57) | AKT1GAB1IRS1KDM4ERARB | |
| SCHEMBL22105971 | 0.81 | TDP1 (0.38) | AKT1GAB1IRS1GFERTDP1 | |
| SCHEMBL22080190 | 0.81 | KDM4E (0.49) | AKT1GAB1IRS1KDM4ETDP1 | |
| SCHEMBL24257838 | 0.80 | TDP1 (0.68) | KDM4ETDP1 | |
| SCHEMBL24257935 | 0.79 | SMN1; SMN2 (0.40) | AKT1GAB1IRS1KDM4ETDP1 | |
| SCHEMBL31682020 | 0.78 | TBXA2R (0.43) | AKT1GAB1IRS1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181223-A1 | INSULIN CONJUGATES | SANOFI (FR) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181223-A1 | INSULIN CONJUGATES | IAPP, INSR, IGF1R | AKT1 1118/4885GAB1 1471/4885IRS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.